New hope for kids with Tough-to-Treat neuroblastoma?

NCT ID NCT02308527

Completed Disease control Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps children with neuroblastoma that has returned or not responded to treatment. The trial enrolled 225 children aged 1 to 21. Researchers looked at tumor shrinkage and how long the disease stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) plus chemotherapy (temozolomide, irinotecan, or topotecan)
What this could lead to: If successful, this combination could offer a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is a phase 2 trial, so results are still preliminary. The added drugs may increase side effects without improving outcomes, and not all children will respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Hopital des Enfants

Toulouse, 31059, France
Instituto de Investigacion Sanitaria

Valencia, 46026, Spain
Natasha van Eijkelenburg

Utrecht, Netherlands
Ospedale Pediatrico Bambino Gseu

Rome, 00165, Italy
Our Ladys Children's Hospital Dublin

Dublin, Dublin 12, Ireland
St Anna Children's Hospital and CCRI/Studies and Statistics

Vienna, A-1090, Austria
Swiss Paediatric Oncology Group

Bern, 3008, Switzerland
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

Sutton, Surrey, SM2 5PT, United Kingdom
University Hospital

Ghent, Belgium
University Hospital Rigshospitalet

Copenhagen, DK-2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.